Emergency approval for DRDO's anti-Covid drug 2-DG; trials claim reduced oxygen dependence, faster recovery
Dr Anant Narayan Bhatt & Dr Sudhir Chandna, Institute of Nuclear Medicine & Allied Sciences(INMAS-DRDO) scientists speak about drug 2-deoxy-D-glucose (2-DG). DCGI approved emergency use of its therapeutic application as adjunct therapy in moderate to severe COVID patients. Watch
READ MORE:
Other Pharmaceuticals Videos
AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence
The brutal leadership lesson that shaped Dr. Reddy’s chief
We are discovery rich, but development poor
Budget 2026: India’s pharma leap, BioPharma SHAKTI gets ₹10K cr; 1,000 clinical trial sites planned
Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma
